Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

BioMap

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 2

  1. OptoSeeker Extends Instruments Toward AI-Assisted Wet Labs

    36氪 reports that OptoSeeker is combining self-developed life-science instruments, AI models, laboratory automation, hardware-software coordination, and data capabilities to explore intelligent wet-lab solutions. Its commercial OptoBot 1000 integrates optical tweezers, microfluidics, imaging, and automated control, while the company is also developing a life-science agent and has reported partnerships spanning AI models, sequencing, and omics services. The report describes deployments and financing, but its single-source, company-profile format leaves performance and commercialization claims unverified.

    36氪 人工智能 · 🔥 0
  2. ByteDance AI drug spinout Anew Labs raises $290M angel round

    Anew Labs, which spun out of ByteDance in June 2026, raised a $290 million angel round in September 2026 at a reported valuation of about 10 billion yuan, which the report calls China's first AI drug-discovery company to reach that valuation in a first round. Investors include Sequoia China, IDG Capital, Hillhouse Venture Capital, Five Source Capital, Gaorong Ventures, Primavera Venture Partners and Boyu Capital, with Sino Biopharmaceutical and the Shanghai Future Industry Fund joining as strategic investors; ByteDance remains the controlling shareholder and continues to supply Volcano Engine compute. The company has released biological AI models Protenix and PXDesign along with AnewMind, a scientific reasoning model for drug-development decisions, and lists four preclinical pipeline assets, with a lead oral small-molecule candidate it describes as the world's first to target both IL-17A and IL-17F, currently in preclinical lead optimization. Anew Labs said it is focused on R&D and declined an interview.

    虎嗅 AI · 🔥 0

Experience and discussion from the community

Share my BioMap experienceAsk about BioMap

Nobody has shared their experience with BioMap yet.